Abiologics

Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to computationally design Synteins de novo using a broad set of artificial building blocks, far beyond the 20 naturally occurring amino acids that form the basis of today’s biologic medicines. Synteins have powerful, desirable pharmacological properties, and can be programmed to interact with virtually any therapeutic target while evading the body’s natural defenses, offering significant advantages compared to today’s biologics, such as less frequent dosing, oral delivery and the ability to reach parts of the body that were previously impossible to access and treat.